However, these previous studies were only conducted in patients with acute respiratory failure who underwent venovenous ECMO; thus, future trials are necessary to confirm the effect of AT III supplementation on clinical outcomes in patients with circulatory failure who underwent venoarterial ECMO. This evidence concerns the gene SERPINC1 and respiratory failure.